155 related articles for article (PubMed ID: 38603793)
1. Re: Epidemiology of giant cell arteritis in Waikato, Aotearoa New Zealand.
Modesto Dos Santos V; Arruda Modesto Sugai T
N Z Med J; 2024 Apr; 137(1593):93-95. PubMed ID: 38603793
[TBL] [Abstract][Full Text] [Related]
2. Epidemiology of giant cell arteritis in Waikato, Aotearoa New Zealand.
van Dantzig P; Quincey V; Kurz J; Ming C; Kamalaksha S; White D
N Z Med J; 2024 Mar; 137(1592):14-21. PubMed ID: 38513200
[TBL] [Abstract][Full Text] [Related]
3. The epidemiology of giant cell arteritis in Otago, New Zealand: a 9-year analysis.
Abdul-Rahman AM; Molteno AC; Bevin TH
N Z Med J; 2011 Feb; 124(1329):44-52. PubMed ID: 21475359
[TBL] [Abstract][Full Text] [Related]
4. Pan American League of Associations for Rheumatology guidelines for the treatment of giant cell arteritis.
Scolnik M; Brance ML; Fernández-Ávila DG; Inoue Sato E; de Souza AWS; Magri SJ; Saldarriaga-Rivera LM; Ugarte-Gil MF; Flores-Suarez LF; Babini A; Zamora NV; Acosta Felquer ML; Vergara F; Carlevaris L; Scarafia S; Soriano Guppy ER; Unizony S;
Lancet Rheumatol; 2022 Dec; 4(12):e864-e872. PubMed ID: 38261393
[TBL] [Abstract][Full Text] [Related]
5. History of primary vasculitis in Latin America.
Iglesias Gammara A; Coral P; Quintana G; Toro CE; Flores LF; Matteson EL; Restrepo JF
Med Sci Monit; 2010 Mar; 16(3):RA58-72. PubMed ID: 20190698
[TBL] [Abstract][Full Text] [Related]
6. Incidence and Prevalence of Polymyalgia Rheumatica and Giant Cell Arteritis in a Healthcare Management Organization in Buenos Aires, Argentina.
Martínez Perez JM; Mollerach FB; Scaglioni V; Vergara F; Gandino IJ; Catoggio LJ; Rosa JE; Soriano ER; Scolnik M
J Rheumatol; 2023 Jan; 50(1):93-97. PubMed ID: 36243415
[TBL] [Abstract][Full Text] [Related]
7. Giant cell arteritis.
Pepper K
Postgrad Med; 2023 Jan; 135(sup1):22-32. PubMed ID: 37021621
[TBL] [Abstract][Full Text] [Related]
8. [Toward a model of communications in public health in Latin America and the Caribbean].
Macías-Chapula CA
Rev Panam Salud Publica; 2005 Dec; 18(6):427-38. PubMed ID: 16536929
[TBL] [Abstract][Full Text] [Related]
9. Incidence and prevalence of large vessel vasculitis (giant cell arteritis and Takayasu arteritis) in northern Italy: A population-based study.
Muratore F; Boiardi L; Mancuso P; Restuccia G; Galli E; Marvisi C; Macchioni P; Rossi PG; Salvarani C
Semin Arthritis Rheum; 2021 Aug; 51(4):786-792. PubMed ID: 34148007
[TBL] [Abstract][Full Text] [Related]
10. The geo-epidemiology of temporal (giant cell) arteritis.
Lee JL; Naguwa SM; Cheema GS; Gershwin ME
Clin Rev Allergy Immunol; 2008 Oct; 35(1-2):88-95. PubMed ID: 18286386
[TBL] [Abstract][Full Text] [Related]
11. The Immunopathology of Giant Cell Arteritis Across Disease Spectra.
Robinette ML; Rao DA; Monach PA
Front Immunol; 2021; 12():623716. PubMed ID: 33717128
[TBL] [Abstract][Full Text] [Related]
12. Incidence of giant cell arteritis in Western Norway 1972-2012: a retrospective cohort study.
Brekke LK; Diamantopoulos AP; Fevang BT; Aβmus J; Esperø E; Gjesdal CG
Arthritis Res Ther; 2017 Dec; 19(1):278. PubMed ID: 29246164
[TBL] [Abstract][Full Text] [Related]
13. Giant cell arteritis: A population-based retrospective cohort study exploring incidence and clinical presentation in Canterbury, Aotearoa New Zealand.
Lyne SA; Ruediger C; Lester S; Chapman PT; Shanahan EM; Hill CL; Stamp L
Front Med (Lausanne); 2022; 9():1057917. PubMed ID: 36482913
[TBL] [Abstract][Full Text] [Related]
14. Anti-dementia medication use in Aotearoa New Zealand: An exploratory study using health data from the Integrated Data Infrastructure (IDI).
Chan AHY; Hikaka JA; To E; Cullum S; Ma'u E; Ryan B; Rivera-Rodriguez C; Cheung G
Aust N Z J Psychiatry; 2023 Jun; 57(6):895-903. PubMed ID: 36053008
[TBL] [Abstract][Full Text] [Related]
15. [Large vessel vasculitis: giant cell arteritis and Takayasu arteritis].
Petitpierre S; Bart PA; Leimgruber A; Spertini F; Prior J; Spertini F
Rev Med Suisse; 2007 Apr; 3(108):1056-60, 1062-3. PubMed ID: 17552258
[TBL] [Abstract][Full Text] [Related]
16. [Gynecologic vasculitis revealing a giant cell arteritis: A case report and literature review].
Guillotin V; Mercie P; Duffau P
Rev Med Interne; 2022 Mar; 43(3):181-184. PubMed ID: 35031140
[TBL] [Abstract][Full Text] [Related]
17. [Giant-cell arteritis and Takayasu arteritis: epidemiological, diagnostic and treatment aspects].
Chaigne-Delalande S; de Menthon M; Lazaro E; Mahr A
Presse Med; 2012 Oct; 41(10):955-65. PubMed ID: 22940467
[TBL] [Abstract][Full Text] [Related]
18. Clonal haematopoiesis across the age spectrum of vasculitis patients with Takayasu's arteritis, ANCA-associated vasculitis and giant cell arteritis.
Gutierrez-Rodrigues F; Wells KV; Jones AI; Hironaka D; Rankin C; Gadina M; Sikora KA; Alemu L; Calado RT; Quinn KA; Patel B; Young NS; Grayson PC
Ann Rheum Dis; 2024 Mar; 83(4):508-517. PubMed ID: 38049983
[TBL] [Abstract][Full Text] [Related]
19. Doubled prevalence rates of ANCA-associated vasculitides and giant cell arteritis between 1994 and 2006 in northern Germany.
Herlyn K; Buckert F; Gross WL; Reinhold-Keller E
Rheumatology (Oxford); 2014 May; 53(5):882-9. PubMed ID: 24425780
[TBL] [Abstract][Full Text] [Related]
20. Antimitochondrial Antibodies and Primary Biliary Cholangitis in Patients with Polymyalgia Rheumatica/Giant Cell Arteritis.
Manzo C; Maslinska M; Castagna A; Hysa E; Merante A; Milchert M; Gravina T; Sargin B; Natale M; Ruberto C; Ruotolo G
Medicina (Kaunas); 2021 Apr; 57(4):. PubMed ID: 33917502
[No Abstract] [Full Text] [Related]
[Next] [New Search]
